SB747651A is a potent and selective inhibitor of the enzyme PLK4 (Polo-like kinase 4), which plays a critical role in centriole duplication and cell cycle regulation. Due to its inhibitory action, it is primarily used in research settings to study mitotic processes and cellular division mechanisms. It has shown promise in oncology-related research, particularly in models of cancers that exhibit centrosome amplification, such as certain breast and liver cancers. By disrupting PLK4 activity, SB747651A induces centrosome dysfunction and triggers cell death in rapidly dividing tumor cells, making it a valuable tool compound for validating PLK4 as a therapeutic target. Its application remains confined to preclinical studies, where it helps elucidate the consequences of PLK4 inhibition on tumor growth and genomic stability.